<PRE>
[Federal Register: September 5, 2001 (Volume 66, Number 172)]
[Rules and Regulations]               
[Page 46369-46370]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05se01-6]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 524

 
Ophthalmic and Topical Dosage Form New Animal Drugs; Moxidectin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of a supplemental new animal drug 
application (NADA) filed by Fort Dodge Animal Health. The supplemental 
NADA provides for topical use of a 0.5 percent moxidectin solution on 
cattle for treatment and control of infections of additional life 
stages and species of gastrointestinal roundworms.

DATES: This rule is effective September 5, 2001.

FOR FURTHER INFORMATION CONTACT: Janis Messenheimer, Center for 
Veterinary Medicine (HFV-135), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-7578.

SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, Div. of American 
Home Products Corp., 800 Fifth St. NW., Fort Dodge, IA 50501, filed 
supplemental NADA 141-099 that provides for use of Cydectin<Register> 
(moxidectin) 0.5% Pour-On for Beef and Dairy Cattle at 500 micrograms 
moxidectin per kilogram of body weight for treatment and control of 
infections of additional life stages and species of gastrointestinal 
roundworms. The supplemental NADA is approved as of June 18, 2001, and 
the regulations are amended in 21 CFR 524.1451 to reflect the approval. 
The basis of approval is discussed in the freedom of information 
summary.

[[Page 46370]]

    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
data and information submitted to support approval of this application 
may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, 
between 9 a.m. and 4 p.m., Monday through Friday.
    Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this approval qualifies 
for 3 years of marketing exclusivity beginning June 18, 2001, because 
the supplemental application contains substantial evidence of the 
effectiveness of the drug involved, any studies of animal safety or, in 
the case of food-producing animals, human food safety studies (other 
than bioequivalence or residue studies) required for approval of the 
application and conducted or sponsored by the applicant.
    The agency has determined under 21 CFR 25.33(a)(1) that this action 
is of a type that does not individually or cumulatively have a 
significant impact on human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 524

    Animal drugs.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
the authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is 
amended as follows:

PART 524--OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

    1. The authority citation for 21 CFR part 524 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.

    2. Section 524.1451 is amended by redesignating paragraph (d) as 
paragraph (e), by removing the last sentence of newly redesignated 
paragraph (e)(3), by adding new paragraph (d), and by revising newly 
redesignated paragraph (e)(2) to read as follows.


Sec. 524.1451  Moxidectin.

* * * * *
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e)  *  *  *  
    (2) Indications for use. Beef and dairy cattle: For treatment and 
control of internal and external parasites: gastrointestinal roundworms 
(Ostertagia ostertagi (adult and L4, including inhibited larvae), 
Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), 
T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. 
pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. 
surnabada (adult and L4), Bunostomum phlebotomum (adult), 
Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult 
and L4)); lungworms (Dictyocaulus viviparus, adult and L4); cattle 
grubs (Hypoderma bovis, H. lineatum); mites (Chorioptes bovis, 
Psoroptes ovis (P. communis var. bovis)); lice (Linognathus vituli, 
Haematopinus eurysternus, Solenopotes capillatus, Bovicola(Damalinia) 
bovis); and horn flies (Haematobia irritans). To control infections and 
to protect from reinfection with H. placei for 14 days after treatment, 
O. radiatum and O. ostertagi for 28 days after treatment, and D. 
viviparus for 42 days after treatment.
* * * * *

    Dated: August 24, 2001.
Claire M. Lathers,
Director, Office of New Animal Drug Evaluation, Center for Veterinary 
Medicine.
[FR Doc. 01-22200 Filed 9-4-01; 8:45 am]
BILLING CODE 4160-01-S

</PRE>